Gemphire Therapeutics Inc. (GEMP) saw its shares drop by over 50% in Friday trading, after the company announced the termination of a clinical trial of gemcabene. At 10:51 a.m. EDT, Gemphire shares had fallen to $1.38, down 57.80%, in heavy trading. Earlier in the week, the company announced it amended an agreement with Pfizer, Inc. concerning gemcabene. Shares opened the trading week at $7.55, and have been paused several times on Friday due to trading volatility. (stephen.nakrosis@wsj.com)

(END) Dow Jones Newswires

August 10, 2018 11:18 ET (15:18 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Pfizer Charts.